MAPT and Alzheimer disease: Much evidence from in vitro and in vivo models, and from biomarkers in patients, show Aβ-induced acceleration of tau pathology as a critical trigger for AD, though the exact mechanisms linking Aβ to tau hyperphosphorylation and accumulation are unclear [98–100].